Dr. Jag Khalsa
September 14th 10:50am-12:30pm Round Room
Abstract: Cannabis remains the most illicit drug used in the world today with an estimated 180 million using it regularly. Cannabis use is associated with a wide range of adverse psychosocial and medical/health consequences, the latter involving almost all the physiological systems in the body including CNS, cardiovascular, pulmonary/respiratory, and others. On the other hand, due to the fact that cannabis plant has 500+ chemical constituents of which 104 are cannabinoids some of which have a great potential as medicine. This presentation will discuss the latest research available on two important aspects of cannabis- adverse health effects and its medicinal properties. In addition, this presentation will discuss various management strategies, recent findings from published and on-going research, and funding mechanisms available at NIDA/NIH
Learning Objectives: (1) The nature and extent of health/medical consequences of cannabis; (2) medicinal properties of cannabis/cannabinoids; (3) Funding mechanisms available at NIDA/NIH
References: (1). WHO Management of Substance Abuse: Cannabis, Joint United Nations Program on AIDS. AIDS Epidemic Update, 2015 (http://www.who.int/substance_abuse/publications/cannabis_report/en/).
(2) Substance Abuse and Mental Health Services Administration (2016). 2016 National Survey on Drug Abuse and Health, Office of Applied Studies, Rockville, MD. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf
Currently Dr. Jag Khalsa is a Special Volunteer at the National Institute on Drug Abuse, NIH. With 50+ years of experience in all aspects of drug research including basic, regulatory and clinical research, he served as the Chief of the Medical Consequences of Drug Abuse and Co-occurring infections Branch, Division of Therapeutics and Medical Consequences, the National Institute on Drug Abuse, NIH, DHHS. He received his Ph.D. in neuro-psycho-pharmacology from the University of Mississippi and postdoctoral training in CNS/Cardiovascular pharmacology at SK&F (now GlaxoSmith Kline), and Toxicology at the Stanford Research Institute. As the Chief of MCB, he was responsible for developing and administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, TB, STD, and others) that may include all biochemical and physiological systems. Prior to joining NIDA in 1987, he served for about 10 years as a pharmacologist/toxicologist assessing safety including carcinogenic and teratogenic potential of chemicals [new drugs-INDs and NDAs] and food additives) and clinical evaluator (adverse consequences of drugs) at the US Food & Drug Administration. He has several publications in the field of pharmacology, toxicology, epidemiology and medicine. He has received numerous awards of meritorious/distinguished service including from the FDA Commissioner, Director of Bureau of Foods, FDA, NIDA Directors, NIH Director, Society on NeuroImmunePharmacology, Life Time Achievement Awards from the International Conference on Molecular Medicine, Neuroimmune Pharmacology and Personalized-Nanomedicine, and a commendation from the US Congressman Cummings.
Dr. Khalsa also has degrees in Chemistry (BS), pharmacy (B.Pharm), pharmacology/pharmacognosy [herbal pharmacology], M.Pharm). Dr. Khalsa’s hobbies are: music and photography. He can be reached via E-mail: email@example.com; firstname.lastname@example.org